Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR 71 Net Cash per Share is kr0.06 as of Jun. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 294 Medical Devices & Instruments companies, Medclair AB ranks worse than 86.73% on this metric.
The historical rank and industry rank for Medclair AB's Net Cash per Share or its related term are showing as below:
NGM:MCLR'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 16.81 Med: 31.99 Max: 48.67
Current: 48.67
During the past 11 years, the highest Price-to-Net-Cash Ratio of Medclair AB was 48.67. The lowest was 16.81. And the median was 31.99.
NGM:MCLR's Price-to-Net-Cash is ranked worse than 86.73% of 294
companies
in the Medical Devices & Instruments industry
Industry Median: 9.21
vs NGM:MCLR: 48.67
Medclair AB (NGM:MCLR) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Medclair AB Net Cash per Share Related Terms
Medclair AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Medclair AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, Medclair AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Medclair AB's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Medclair AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a Net Cash per Share of kr0.06 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #255 out of 294 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is Medclair AB's Net Cash per Share too high?
Medclair AB's current Net Cash per Share is kr0.06. Based on the distribution chart, Medclair AB ranks #255 out of 294 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #255 out of 294 companies for Net Cash per Share. This places Medclair AB in the lower half of its industry. The industry median Net Cash per Share is 9.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.21, based on 294 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current Net Cash per Share is kr0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.22, compared to a current price of kr2.92 — trading 31.5% above its estimated fair value. The current Net Cash per Share is kr0.06. Medclair AB's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Net Cash per Share is kr0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.92 is trading 31.5% above its estimated GF Value™ of kr2.22.
GuruFocus considers Medclair AB to be Significantly Overvalued.
Key valuation signals for NGM:MCLR:
Net Cash per Share: kr0.06
GF Value™: kr2.22 vs. price of kr2.92 (31.5% above fair value)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
